RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Gabriel Odom to Buprenorphine

Back to Details
This is a "connection" page, showing publications Gabriel Odom has written about Buprenorphine.
Gabriel Odom
Connection Strength
0.449
Buprenorphine
  1. Luo SX, Feaster DJ, Liu Y, Balise RR, Hu MC, Bouzoubaa L, Odom GJ, Brandt L, Pan Y, Hser YI, VanVeldhuisen P, Castillo F, Calderon AR, Rotrosen J, Saxon AJ, Weiss RD, Wall M, Nunes EV. Individual-Level Risk Prediction of Return to Use During Opioid Use Disorder Treatment. JAMA Psychiatry. 2024 Jan 01; 81(1):45-56.
    View in: PubMed
    Score: 0.231
  2. Brandt L, Hu MC, Liu Y, Castillo F, Odom GJ, Balise RR, Feaster DJ, Nunes EV, Luo SX. Risk of Experiencing an Overdose Event for Patients Undergoing Treatment With Medication for Opioid Use Disorder. Am J Psychiatry. 2023 05 01; 180(5):386-394.
    View in: PubMed
    Score: 0.218
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support